Daniel L. Zheng

FDA investigator

Appears on 24 documents from 2020 to 2026, most often at sites in Massachusetts. Most often cites production record review (21 CFR 211.192).

24
Documents on file
6.0
Observations per 483
2020
First seen
2026
Most recent

What they cite most

From 141 observations

Activity by year

2020: 1, 2021: 3, 2022: 5, 2023: 4, 2024: 4, 2025: 6, 2026: 1

Where

Massachusetts 11 · India 2 · New Jersey 2 · New York 2 · Rhode Island 2 · Florida 1

Is Daniel L. Zheng coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

24 documents, newest first
FirmOpen
483 Lantheus Medical Imaging, Inc.Apr 9, 2026
483 Fresenius Kabi Compounding, LLCNov 6, 2025 · Canton, Massachusetts
483 Fresenius Kabi Compounding, LLCNov 5, 2025 · Canton, Massachusetts
483 A.I.G. TECHNOLOGIES, INC.May 16, 2025 · POMPANO BEACH, Florida
483 Sun Pharmaceutical Industries, Inc.Apr 18, 2025 · Billerica, Massachusetts
483 Bausch & Lomb IncorporatedFeb 27, 2025 · Greenville, South Carolina
483 Rentschler Biopharma Inc.Jan 17, 2025 · Milford, Massachusetts

About this profile

What does Daniel L. Zheng inspect?

Daniel L. Zheng appears on 24 documents on file covering 22 sites, most often in Massachusetts.

What do they cite most often?

21 CFR 211.192 (production record review), followed by 21 CFR 211.42 and 21 CFR 211.22.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Daniel L. Zheng is dated Apr 9, 2026.